Drug updated on 5/1/2024
Dosage Form | Capsule (oral: 50 mg, 75 mg) |
Drug Class | Farnesyltransferase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford progeria syndrome.
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above for treatment of processing-deficient progeroid laminopathies with heterozygous LMNA mutation with progerin-like protein accumulation.
- Indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above for treatment of processing-deficient progeroid laminopathies with homozygous or compound heterozygous ZMPSTE24 mutations.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Zokinvy (lonafarnib) Prescribing Information. | 2020 | Eiger BioPharmaceuticals Inc., Palo Alto, CA |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford Progeria Syndrome. | 2016 | Circulation |